Phialogics, a spin-off of the Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, is a preclinical biotech company dedicated to the development of therapeutics to treat patients with autoimmune diseases. The company’s expertise combines cutting edge protein engineering technology with a deep understanding of the human immune system. Phialogics has setup a pipeline to develop next-generation biologics that restore immune tolerance in autoimmune disease and prevent immune mediated tissue damage. Phialogics’ technology platform is based on modular bi-specific biologics that selectively target either disease causing immune cell types or enrich in diseased compartments in the human body. Company’s focus is on autoimmune disorders with high unmet medical need in order to make a difference for patients and their families.